Pharmacologic class (EPC) · 5 drug pages

Calcium-sensing receptor agonist: adverse event reports filed with FDA

47,026 reports list a drug in this class as a suspect or interacting product, 2004–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

47,026
reports across the class: 0.2% of all reports; 240
reports, 12 months to June 2026: 433 in the 12 months before; 35.7%
marked serious by the reporter: 57.4% across all reports; 5
drugs with a page: brand and generic names counted separately

Calcium-sensing receptor agonist is a pharmacologic class (an FDA Established Pharmacologic Class) with 5 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 47,026 adverse event reports received by FDA, 0.2% of the database, from March 2004 to June 2026.

240 reports arrived in the 12 months to June 2026, down 45% from 433 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 35.7% of the class's reports are marked serious, 5.3% record death among the outcomes and 23.2% record hospitalisation, as reported.

Across the class the reactions recorded most often are drug dose omission (18.4%), hospitalisation (14.7%) and laboratory test abnormal (9%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
SensiparCinacalcet hydrochloride	brand	40,949	14	30.5%	Drug dose omission
Cinacalcet hydrochloride	generic	2,226	102	92.9%	Off label use
ParsabivEtelcalcetide	brand	2,190	14	33.9%	Underdose
Cinacalcet	generic	1,093	94	84.8%	Drug ineffective
Etelcalcetide	generic	568	16	98.4%	Shunt stenosis

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Drug dose omissiona dose was missed18.4%8,676
Hospitalisationadmission to hospital14.7%6,923
Laboratory test abnormal9%4,215
Off label useused for a purpose or in a way not on the label5.6%2,639
Nauseafeeling sick4.9%2,307
Intentional product misusedeliberate use not as intended4.4%2,081
Deaththe patient died; cause not stated by this term3.9%1,851
Malaisegeneral feeling of being unwell3.2%1,498
Vomitingbeing sick3.2%1,498
Adverse drug reactiona harmful or unpleasant reaction reported to a medicine3.1%1,438
Diarrhoealoose or frequent stools2.2%1,055
Abdominal discomfortstomach discomfort1.7%790
Decreased appetitereduced appetite1.7%784
Blood parathyroid hormone increased1.5%697
Drug ineffectivethe medicine did not work as expected1.5%696
Hypocalcaemialow blood calcium1.4%635
Muscle spasmsmuscle cramps1.3%602
Abdominal pain upperupper stomach pain1.1%502
Unevaluable eventthe event could not be assessed1%492
Dizzinesslight-headedness or unsteadiness1%468
Adverse eventan unwanted medical event, type not specified1%457
Blood calcium decreased1%456
Hypotensionlow blood pressure0.8%391
Blood parathyroid hormone abnormal0.8%364
Pruritusitching0.7%341

Solid bar: share of all class reports. Hollow bar: the median share across the 5 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death5.3%2,515

Life-threatening0.7%341

Hospitalisation (initial or prolonged)23.2%10,918

Disability0.8%398

Congenital anomaly0%3

Other serious23.3%10,965

Not serious64.3%30,236

Patient age

Under 20.1%40

2 to 110.1%63

12 to 170.1%47

18 to 449.5%4,465

45 to 6426.8%12,604

65 to 7413.1%6,165

75 and over9%4,240

Age not given41.3%19,402

Who reported

Physician10%4,721

Pharmacist30.9%14,509

Other health professional30.1%14,161

Lawyer0%1

Consumer or non-health professional28.5%13,399

Not given0.5%235

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about Calcium-sensing receptor agonist reports

Which drugs are in the Calcium-sensing receptor agonist class on this site?

Sensipar, Cinacalcet hydrochloride, Parsabiv, Cinacalcet and Etelcalcetide. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

47,026 reports through June 2026, 240 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

drug dose omission (18.4%), hospitalisation (14.7%), laboratory test abnormal (9%), off label use (5.6%) and nausea (4.9%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.